

# ISO 13022:2012-04 (E)

## Medical products containing viable human cells - Application of risk management and requirements for processing practices

---

<b>Contents</b>		<b>Page</b>
Foreword .....		iv
Introduction .....		v
<b>1</b>	<b>Scope .....</b>	<b>1</b>
<b>2</b>	<b>Normative references .....</b>	<b>2</b>
<b>3</b>	<b>Terms and definitions .....</b>	<b>2</b>
<b>4</b>	<b>Risk management process .....</b>	<b>6</b>
<b>4.1</b>	<b>General .....</b>	<b>6</b>
<b>4.2</b>	<b>Hazards associated with the cellular component .....</b>	<b>6</b>
<b>4.3</b>	<b>Risk analysis .....</b>	<b>8</b>
<b>4.4</b>	<b>Risk evaluation .....</b>	<b>9</b>
<b>4.5</b>	<b>Risk control .....</b>	<b>9</b>
<b>4.6</b>	<b>Evaluation of overall residual risk acceptability .....</b>	<b>9</b>
<b>4.7</b>	<b>Production and post-production information system .....</b>	<b>10</b>
<b>Annex B (informative)</b>	<b>Graphic representation of the part of the risk management process for cell-based medical products .....</b>	<b>12</b>
<b>Annex C (normative)</b>	<b>Requirements for donor selection and testing .....</b>	<b>13</b>
<b>Annex D (informative)</b>	<b>Guidance for tissue procurement .....</b>	<b>17</b>
<b>Annex E (normative)</b>	<b>Requirements for handling of cells and tissue during manufacture .....</b>	<b>20</b>
<b>Annex F (normative)</b>	<b>Requirements for packaging and labelling .....</b>	<b>23</b>
<b>Annex G (informative)</b>	<b>Guidance for transport .....</b>	<b>26</b>
<b>Annex H (informative)</b>	<b>Guidance for storage .....</b>	<b>31</b>
<b>Annex I (normative)</b>	<b>Requirements for traceability .....</b>	<b>34</b>
<b>Annex J (normative)</b>	<b>Risk reduction measures relating to contamination with viruses and other infectious agents such as TSE .....</b>	<b>35</b>
<b>Annex K (informative)</b>	<b>Guidance relating to hazards caused by the tumorigenic potential of human cells or tissues used for the production of medical products .....</b>	<b>38</b>
<b>Annex L (informative)</b>	<b>Guidance relating to microbiological contamination .....</b>	<b>39</b>
<b>Annex M (informative)</b>	<b>Guidance relating to potential adverse effects of non-cellular residues of the product .....</b>	<b>40</b>
<b>Annex N (normative)</b>	<b>Requirements relating to potential adverse effects of the cellular components of a medical product .....</b>	<b>41</b>

<b>Annex O (informative) Guidance for the characterization of the cellular components of a medical product .....</b>	<b>42</b>
<b>Annex P (informative) Clinical evaluation and testing .....</b>	<b>45</b>
<b>Bibliography .....</b>	<b>46</b>